Loyse, A;
Burry, J;
Cohn, J;
Ford, N;
Chiller, T;
Ribeiro, I;
Koulla-Shiro, S;
Mghamba, J;
Ramadhani, A;
Nyirenda, R;
et al.
Loyse, A; Burry, J; Cohn, J; Ford, N; Chiller, T; Ribeiro, I; Koulla-Shiro, S; Mghamba, J; Ramadhani, A; Nyirenda, R; Aliyu, SH; Wilson, D; Le, T; Oladele, R; Lesikari, S; Muzoora, C; Kalata, N; Temfack, E; Mapoure, Y; Sini, V; Chanda, D; Shimwela, M; Lakhi, S; Ngoma, J; Gondwe-Chunda, L; Perfect, C; Shroufi, A; Andrieux-Meyer, I; Chan, A; Schutz, C; Hosseinipour, M; Van der Horst, C; Klausner, JD; Boulware, DR; Heyderman, R; Lalloo, D; Day, J; Jarvis, JN; Rodrigues, M; Jaffar, S; Denning, D; Migone, C; Doherty, M; Lortholary, O; Dromer, F; Stack, M; Molloy, SF; Bicanic, T; van Oosterhout, J; Mwaba, P; Kanyama, C; Kouanfack, C; Mfinanga, S; Govender, N; Harrison, TS
(2019)
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
Lancet Infect Dis, 19 (4).
e143-e147.
ISSN 1474-4457
https://doi.org/10.1016/S1473-3099(18)30493-6
SGUL Authors: Bicanic, Tihana Loyse, Angela
![]() |
Microsoft Word (.docx)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (573kB) |
Abstract
In 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and cryptococcal antigen screening programmes for ambulatory people living with HIV who access care. WHO's preferred therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucytosine. In the ACTA trial, 1-week (short course) amphotericin B plus flucytosine resulted in a 10-week mortality of 24% (95% CI -16 to 32) and 2 weeks of fluconazole and flucytosine resulted in a 10-week mortality of 35% (95% CI -29 to 41). However, with widely used fluconazole monotherapy, mortality because of HIV-related cryptococcal meningitis is approximately 70% in many African LMIC settings. Therefore, the potential to transform the management of HIV-related cryptococcal meningitis in resource-limited settings is substantial. Sustainable access to essential medicines, including flucytosine and amphotericin B, in LMICs is paramount and the focus of this Personal View.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | ||||||||
Keywords: | 1103 Clinical Sciences, 1108 Medical Microbiology, Microbiology | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||||
Journal or Publication Title: | Lancet Infect Dis | ||||||||
ISSN: | 1474-4457 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 | ||||||||
PubMed ID: | 30344084 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/110262 | ||||||||
Publisher's version: | https://doi.org/10.1016/S1473-3099(18)30493-6 |
Statistics
Actions (login required)
![]() |
Edit Item |